Founded in 2020, Ilimex designs, supplies and validates cutting-edge air-treatment technologies that achieve Log-6 (99.9999%) pathogen reduction in a single pass. Its newest product, Flufence, continuously detects airborne pathogens and applies high-intensity UVC light to neutralise viruses such as Avian Influenza, targeting intensive poultry production and medicinal mushroom cultivation. Trials in mushroom facilities showed an overall drop in contaminant pathogens when the Ilimex system was operating. Management estimates the initial global poultry air-cleaning market at roughly £4 billion and the mushroom-sector opportunity at about £3.5 billion across the UK, US and EU. The company’s strategy is to deploy Flufence with key customer partners to gather independent performance data that links air sterilisation to production efficiency and profitability. Demand for its high-level biosecurity solutions is expanding as airborne contamination threatens regulatory compliance and bottom-line results in agri-food settings. Ilimex positions its technology as providing market-leading biosecurity and aims to capitalise on significant local and global opportunities. The recent seed financing strengthens its balance sheet and supports validation and commercial rollout of Flufence.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Nov 2025